SWX:GALDPharmaceuticals
Galderma’s Record Sales Recast Growth Story Around Nemluvio And Aesthetics
Galderma Group (SWX:GALD) reports full year sales above $5b, marking a milestone for its dermatology focused portfolio.
The company highlights new product launches it describes as having blockbuster potential across its prescription and aesthetics segments.
Fresh clinical data show Nemluvio delivering long term efficacy and safety in prurigo nodularis, an area of high unmet medical need.
Regulatory approval of new device technology supports further expansion of Galderma's aesthetics...